Ascendiant Capital Starts Repros Therapeutics (RPRX) at Strong Buy; Advancing Two Products Into Phase 3 Makes Shares Attractive
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $61.26 -0.76%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Ascendiant Capital initiates coverage on Repros Therapeutics (NASDAQ: RPRX) with a Strong Buy. PT $6.00.
Analyst, Kaey Nakae, said, "Repros is a small-cap biotech company that is developing two key products. The first, Androxal, is a once daily, oral therapy for the treatment of low testosterone due to secondary hypogonadism. The second, Proellex, is an orally administered selective blocker of the progesterone receptor in women for the treatment of uterine fibroids and endometriosis. We expect the Company to advance both drugs into Phase 3 studies this year. The market opportunity for each drug exceeds $1 billion."
For an analyst ratings summary and ratings history on Repros Therapeutics click here. For more ratings news on Repros Therapeutics click here.
Shares of Repros Therapeutics closed at $4.06 yesterday.
Analyst, Kaey Nakae, said, "Repros is a small-cap biotech company that is developing two key products. The first, Androxal, is a once daily, oral therapy for the treatment of low testosterone due to secondary hypogonadism. The second, Proellex, is an orally administered selective blocker of the progesterone receptor in women for the treatment of uterine fibroids and endometriosis. We expect the Company to advance both drugs into Phase 3 studies this year. The market opportunity for each drug exceeds $1 billion."
For an analyst ratings summary and ratings history on Repros Therapeutics click here. For more ratings news on Repros Therapeutics click here.
Shares of Repros Therapeutics closed at $4.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold
- Piper Sandler Starts Madison Square Garden Entertainment (MSGE) at Neutral
- Craig-Hallum Starts Quince Therapeutics Inc. (QNCX) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
